{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T16:28:32Z","timestamp":1785601712220,"version":"3.56.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Here, we evaluate the impact of etrasimod 2 mg QD on health-related quality of life (HRQoL) in patients with UC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This post hoc analysis used data from the Phase 3 randomized controlled trials, ELEVATE UC 52 and ELEVATE UC 12. HRQoL measures included: Inflammatory Bowel Disease Questionnaire (IBDQ), 36-Item Short Form Survey (SF-36), and Work Productivity and Activity Impairment Questionnaire: Ulcerative Colitis (WPAI:UC) completed at baseline, Week 12 (both trials), and Week 52 (ELEVATE UC 52 only). For IBDQ analyses, patients were stratified by prior exposure to biologics\/Janus kinase inhibitors (JAKi) and baseline modified Mayo score (MMS; 4-6 or 7-9).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Generally, significantly greater proportions of patients receiving etrasimod (N\u2005=\u2005527) vs placebo (N\u2005=\u2005260) achieved IBDQ remission (IBDQ total score \u2265170) and IBDQ response (IBDQ total score increase from baseline \u226516), with significant improvement in all IBDQ domain scores at Week 12 and maintained through Week 52. Significant differences in IBDQ remission and IBDQ response rates between etrasimod and placebo were more consistent among biologic\/JAKi-naive patients vs those who were biologic\/JAKi-experienced and in those with baseline MMS 7-9 vs 4-6. Significant improvements were observed in several SF-36 domain and summary scores and WPAI:UC domain scores at Week 12 and Week 52.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Etrasimod 2 mg QD demonstrated significant and clinically meaningful improvements across multiple HRQoL measures, including WPAI, vs placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trial Registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov: NCT03945188; NCT03996369<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izae229","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T20:04:52Z","timestamp":1727381092000},"page":"1583-1594","source":"Crossref","is-referenced-by-count":4,"title":["Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12"],"prefix":"10.1093","volume":"31","author":[{"given":"Alessandro","family":"Armuzzi","sequence":"first","affiliation":[{"name":"IBD Unit, IRCCS Humanitas Research Hospital , Milan ,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T","family":"Rubin","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine Inflammatory Bowel Disease Center , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel University , Kiel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Pan\u00e9s","sequence":"additional","affiliation":[{"name":"Formerly Department of Gastroenterology, Hospital Cl\u00ednic de Barcelona, IDIBAPS, Centro de Investigac\u00edon Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd) , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-698X","authenticated-orcid":false,"given":"Marc","family":"Fellmann","sequence":"additional","affiliation":[{"name":"Pfizer AG , Z\u00fcrich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Bartolome","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gruben","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Groton, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Goetsch","sequence":"additional","affiliation":[{"name":"Pfizer AG , Z\u00fcrich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Bhattacharjee","sequence":"additional","affiliation":[{"name":"Pfizer Healthcare India Pvt. Ltd , Chennai ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Chaparro","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), CIBERehd , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4968-5795","authenticated-orcid":false,"given":"Marla C","family":"Dubinsky","sequence":"additional","affiliation":[{"name":"Susan and Leonard Feinstein IBD Center, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"issue":"10080","key":"2025061403571339200_CIT0001","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet."},{"issue":"6","key":"2025061403571339200_CIT0002","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis."},{"issue":"10401","key":"2025061403571339200_CIT0003","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet."},{"issue":"1","key":"2025061403571339200_CIT0004","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.crohns.2007.06.005","article-title":"Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn\u2019s and Ulcerative Colitis Associations (EFCCA) patient survey","volume":"1","author":"Ghosh","year":"2007","journal-title":"J Crohns Colitis."},{"issue":"5","key":"2025061403571339200_CIT0005","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/flgastro-2021-102027","article-title":"Inflammatory bowel disease negatively impacts household and family life","volume":"13","author":"Paulides","year":"2022","journal-title":"Frontline Gastroenterol"},{"issue":"1","key":"2025061403571339200_CIT0006","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12876-020-1164-0","article-title":"The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe","volume":"20","author":"Armuzzi","year":"2020","journal-title":"BMC Gastroenterol."},{"issue":"11","key":"2025061403571339200_CIT0007","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/ibd\/izab016","article-title":"Ulcerative Colitis Narrative Global Survey findings: the impact of living with ulcerative colitis-patients\u2019 and physicians\u2019 view","volume":"27","author":"Dubinsky","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2025061403571339200_CIT0008","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ibd.20793","article-title":"Impact of ulcerative colitis from patients\u2019 and physicians\u2019 perspectives: results from the UC: NORMAL survey","volume":"15","author":"Rubin","year":"2009","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2025061403571339200_CIT0009","doi-asserted-by":"publisher","first-page":"7682","DOI":"10.1038\/s41598-022-11911-4","article-title":"Prevalence of anxiety and depressive symptoms in ulcerative colitis patients in Jordan and its relationship to patient-reported disease activity","volume":"12","author":"Abu Sneineh","year":"2022","journal-title":"Sci Rep."},{"issue":"8","key":"2025061403571339200_CIT0010","doi-asserted-by":"publisher","first-page":"e28502","DOI":"10.7759\/cureus.28502","article-title":"Quality of life in patients with inflammatory bowel disease: importance of psychological symptoms","volume":"14","author":"Mitropoulou","year":"2022","journal-title":"Cureus"},{"key":"2025061403571339200_CIT0011","doi-asserted-by":"publisher","first-page":"101986","DOI":"10.1016\/j.eclinm.2023.101986","article-title":"Longitudinal trajectories of anxiety, depression, and bipolar disorder in inflammatory bowel disease: a population-based cohort study","volume":"59","author":"Bisgaard","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"2","key":"2025061403571339200_CIT0012","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.dld.2016.09.009","article-title":"Patient preferences for inflammatory bowel disease treatment objectives","volume":"49","author":"Casellas","year":"2017","journal-title":"Dig Liver Dis."},{"issue":"13","key":"2025061403571339200_CIT0013","doi-asserted-by":"publisher","first-page":"7159","DOI":"10.3390\/ijerph18137159","article-title":"Role of quality of life as endpoint for inflammatory bowel disease treatment","volume":"18","author":"Calvino-Suarez","year":"2021","journal-title":"Int J Environ Res Public Health."},{"issue":"5","key":"2025061403571339200_CIT0014","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"23","key":"2025061403571339200_CIT0015","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.3390\/jcm10235551","article-title":"Treatment targets in ulcerative colitis: is it time for all in, including histology","volume":"10","author":"Wetwittayakhlang","year":"2021","journal-title":"J Clin Med"},{"issue":"9","key":"2025061403571339200_CIT0016","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.3390\/jcm11092302","article-title":"An update on current pharmacotherapeutic options for the treatment of ulcerative colitis","volume":"11","author":"Ferretti","year":"2022","journal-title":"J Clin Med"},{"issue":"10","key":"2025061403571339200_CIT0017","first-page":"795","article-title":"Overcoming adherence issues in ulcerative colitis","volume":"3","author":"Kane","year":"2007","journal-title":"Gastroenterol Hepatol (NY)"},{"issue":"3","key":"2025061403571339200_CIT0018","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/ecco-jcc\/jjac145","article-title":"What are the unmet needs and most relevant treatment outcomes according to patients with inflammatory bowel disease? A qualitative patient preference study","volume":"17","author":"Schoefs","year":"2023","journal-title":"J Crohns Colitis."},{"issue":"7","key":"2025061403571339200_CIT0019","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.dld.2021.03.002","article-title":"Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: a narrative review","volume":"53","author":"Armuzzi","year":"2021","journal-title":"Dig Liver Dis."},{"issue":"10383","key":"2025061403571339200_CIT0020","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet."},{"issue":"3","key":"2025061403571339200_CIT0021","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/0016-5085(89)90905-0","article-title":"A new measure of health status for clinical trials in inflammatory bowel disease","volume":"96","author":"Guyatt","year":"1989","journal-title":"Gastroenterology."},{"key":"2025061403571339200_CIT0022","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/B978-0-12-804217-5.00023-0","article-title":"Chapter 23\u2014health-related quality-of-life tools\u2014immune disorders","volume-title":"Clinical Trials","author":"Brody","year":"2016","edition":"2"},{"issue":"1","key":"2025061403571339200_CIT0023","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s41687-018-0088-8","article-title":"Psychometric validation of the work productivity and activity impairment questionnaire in ulcerative colitis: results from a systematic literature review","volume":"2","author":"Yarlas","year":"2018","journal-title":"J Patient Rep Outcomes"},{"issue":"2","key":"2025061403571339200_CIT0024","doi-asserted-by":"publisher","first-page":"e18723","DOI":"10.1097\/MD.0000000000018723","article-title":"Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease","volume":"99","author":"Huoponen","year":"2020","journal-title":"Medicine (Baltim)."},{"issue":"2","key":"2025061403571339200_CIT0025","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/s0167-6296(01)00130-8","article-title":"The estimation of a preference-based measure of health from the SF-36","volume":"21","author":"Brazier","year":"2002","journal-title":"J Health Econ."},{"issue":"12","key":"2025061403571339200_CIT0026","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1136\/ard.2009.115550","article-title":"Use of \u201cspydergrams\u201d to present and interpret SF-36 health-related quality of life data across rheumatic diseases","volume":"68","author":"Strand","year":"2009","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"2025061403571339200_CIT0027","doi-asserted-by":"publisher","first-page":"otac023","DOI":"10.1093\/crocol\/otac023","article-title":"Work-related productivity loss and associated indirect costs in patients with Crohn\u2019s disease or ulcerative colitis in the United States","volume":"4","author":"Ding","year":"2022","journal-title":"Crohns Colitis 360."},{"issue":"18","key":"2025061403571339200_CIT0028","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"issue":"2","key":"2025061403571339200_CIT0029","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/ecco-jcc\/jjx133","article-title":"Tofacitinib in patients with ulcerative colitis: health-related quality of life in phase 3 randomised controlled induction and maintenance studies","volume":"12","author":"Panes","year":"2018","journal-title":"J Crohns Colitis."},{"issue":"13","key":"2025061403571339200_CIT0030","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med."},{"issue":"4","key":"2025061403571339200_CIT0031","doi-asserted-by":"publisher","first-page":"otad070","DOI":"10.1093\/crocol\/otad070","article-title":"Mirikizumab improves quality of life in patients with moderately-to-severely active ulcerative colitis: results from the phase 3 LUCENT-1 induction and LUCENT-2 maintenance studies","volume":"5","author":"Sands","year":"2023","journal-title":"Crohns Colitis 360."},{"issue":"6","key":"2025061403571339200_CIT0032","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/jpm13060947","article-title":"Quality of life (QoL) in patients with chronic inflammatory bowel diseases: how much better with biological drugs","volume":"13","author":"Bellone","year":"2023","journal-title":"J Pers Med"},{"issue":"7","key":"2025061403571339200_CIT0033","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.crohns.2013.11.017","article-title":"Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study","volume":"8","author":"Gibson","year":"2014","journal-title":"J Crohns Colitis."},{"issue":"5","key":"2025061403571339200_CIT0034","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/ecco-jcc\/jjy024","article-title":"Burden of ulcerative colitis on functioning and well-being: a systematic literature review of the SF-36\u00ae Health Survey","volume":"12","author":"Yarlas","year":"2018","journal-title":"J Crohns Colitis."},{"key":"2025061403571339200_CIT0035","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2147\/PPA.S175026","article-title":"Patients\u2019 perceptions of the impact of ulcerative colitis on social and professional life: results from the UC-LIFE survey of outpatient clinics in Spain","volume":"12","author":"Calvet","year":"2018","journal-title":"Patient Prefer Adherence"},{"issue":"10","key":"2025061403571339200_CIT0036","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/01.mib.0000179467.01748.99","article-title":"Health-related quality of life in patients with inflammatory bowel disease measured with the Short Form-36: psychometric assessments and a comparison with general population norms","volume":"11","author":"Bernklev","year":"2005","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2025061403571339200_CIT0037","doi-asserted-by":"publisher","first-page":"e1004146","DOI":"10.1371\/journal.pmed.1004146","article-title":"The COVID-19 pandemic and health-related quality of life across 13 high- and low-middle-income countries: a cross-sectional analysis","volume":"20","author":"Violato","year":"2023","journal-title":"PLoS Med."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izae229\/60651563\/izae229.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/6\/1583\/60651563\/izae229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/6\/1583\/60651563\/izae229.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T07:57:18Z","timestamp":1749887838000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/6\/1583\/7778239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,9,26]]},"published-print":{"date-parts":[[2025,6,13]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae229","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2024,9,26]]}}}